Cargando…

Synergistic deterioration of prognosis associated with decreased grip strength and hyporesponse to erythropoiesis-stimulating agents in patients undergoing hemodialysis

INTRODUCTION: We examined the combined effect of erythropoietin (EPO) hyporesponsiveness and low handgrip strength (HGS) on the prognosis of patients undergoing hemodialysis (HD). METHODS: We recruited patients with chronic kidney disease (CKD) Stage 5, who were undergoing HD at our dialysis clinic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Shizuka, Tanaka, Kentaro, Hoshino, Junichi, Hara, Shigeko, Kushiyama, Akifumi, Tanaka, Yoshihide, Motonishi, Shuta, Sakai, Ken, Ozawa, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621290/ https://www.ncbi.nlm.nih.gov/pubmed/36305202 http://dx.doi.org/10.1080/0886022X.2022.2106873

Ejemplares similares

Quantitative sonographic assessment of quadriceps muscle thickness for fall injury prediction in patients undergoing maintenance hemodialysis: an observational cohort study
por: Sai, Asuka, et al.
Publicado: (2021)

Association of gait speed and grip strength with risk of cardiovascular events in patients on haemodialysis: a prospective study
por: Kuki, Atsumi, et al.
Publicado: (2019)

Iron deficiency associates with deterioration in several symptoms independently from hemoglobin level among chronic hemodialysis patients
por: Motonishi, Shuta, et al.
Publicado: (2018)

Correction: Iron deficiency associates with deterioration in several symptoms independently from hemoglobin level among chronic hemodialysis patients
por: Motonishi, Shuta, et al.
Publicado: (2018)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

The Resection of Thyroid Cancer Was Associated with the Resolution of Hyporesponsiveness to an Erythropoiesis-stimulating Agent in a Hemodialysis Patient with Aceruloplasminemia
por: Nagata, Soichiro, et al.
Publicado: (2017)

Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
por: Wish, Jay B.
Publicado: (2020)

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection
por: Shah, Hitesh H., et al.
Publicado: (2020)

Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with type 2 diabetes
por: Tanaka, Kentaro, et al.
Publicado: (2015)

Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
por: Cizman, Borut, et al.
Publicado: (2020)

Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients
por: Amnuay, Kamalas, et al.
Publicado: (2019)

Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study
por: Narita, Ichiei, et al.
Publicado: (2022)

In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
por: Ylenia, Ingrasciotta, et al.
Publicado: (2019)

Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
por: Macdougall, Iain C., et al.
Publicado: (2023)

Correction to: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
por: Ingrasciotta, Ylenia, et al.
Publicado: (2020)

ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage
por: Kuragano, Takahiro, et al.
Publicado: (2016)

Selenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Yasukawa, Minoru, et al.
Publicado: (2022)

Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics
por: Gilbertson, David T, et al.
Publicado: (2013)

Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: A retrospective study in Beijing, China
por: Sui, Zhun, et al.
Publicado: (2019)

Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients
por: Sibbel, Scott P., et al.
Publicado: (2015)

Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report
por: Yu, Wei-Hong, et al.
Publicado: (2020)

Erythropoiesis in Murine Myeloid Leukaemia
por: Tanaka, T.
Publicado: (1970)

rHuEPO Hyporesponsiveness and Related High Dosages Are Associated with Hyperviscosity in Maintenance Hemodialysis Patients
por: Erkmen Uyar, Mehtap, et al.
Publicado: (2013)

Erythropoiesis stimulating agents are associated with serum fibroblast growth factor 23 metabolism in patients on hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2020)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Effect of hepatitis C virus infection on erythropoiesis in patients on hemodialysis
por: Saifan, Chadi, et al.
Publicado: (2013)

Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Lee, Yu-Ting, et al.
Publicado: (2022)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

Ionomycin Treatment Renders NK Cells Hyporesponsive
por: Romera-Cárdenas, Gema, et al.
Publicado: (2016)

An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects
por: Cizman, Borut, et al.
Publicado: (2018)

NK Cell Hyporesponsiveness: More Is Not Always Better
por: Frutoso, Marie, et al.
Publicado: (2019)

Immunological hyporesponsiveness in tuberculosis: The role of mycobacterial glycolipids
por: Correia-Neves, Margarida, et al.
Publicado: (2022)

Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
por: Suttorp, Marit M, et al.
Publicado: (2013)

Identification of Prescribing Patterns in Hemodialysis Outpatients Taking Multiple Medications
por: Nagano, Hiroyuki, et al.
Publicado: (2023)

Deterioration of Cerebral Oxygenation by Aortic Arch Calcification Progression in Patients Undergoing Hemodialysis: A Cross-Sectional Study
por: Ito, Kiyonori, et al.
Publicado: (2017)

The implication of calf circumference and grip strength in osteoporosis and bone mineral density among hemodialysis patients
por: Ozawa, Moe, et al.
Publicado: (2022)

Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity
por: Maggi, Jaxaira, et al.
Publicado: (2015)

Factors Influencing Aspirin Hyporesponsiveness in Elderly Chinese Patients
por: Ou, Wei mei, et al.
Publicado: (2019)

Resistance to Erythropoiesis-Stimulating Agents Is Associated with Arterial Microcalcification in Early Hemodialysis Patients
por: Won, Hye Sung, et al.
Publicado: (2014)

Regulation of platelet count by erythropoiesis-stimulating agents – iron axis in hemodialysis patients
por: Koike, Kiyomi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k73ru885cs9mvq53fmilir8hu7